News
NovaBay Pharmaceuticals: Q4 Earnings Insights
26 Mar 24
Earnings
NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate
26 Mar 24
Earnings, News
Earnings Scheduled For March 26, 2024
26 Mar 24
Earnings
Novabay Reported Preliminary 2023 Sales Of $14.7M, Consisting Of $3.6M From Its DERMAdoctor Skincare Segment And $11.1M From Its Eyecare And Wound Care Segment Versus Consensus Of $14.40M
14 Mar 24
Earnings, News, Guidance, Health Care, General
Novabay Reported Preliminary Q4 2023 Sales Of $3.7M, Consisting Of $0.9M From Its DERMAdoctor Skincare Segment And $2.8M From Its Eyecare And Wound Care Segment Versus Consensus Of $3.4M
14 Mar 24
Earnings, News, Guidance, Health Care, General
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 Feb 24
Movers
NovaBay Pharmaceuticals Reports 64% YoY Growth In Avenova Unit Subscription-Based Sales; 38% Increase In Subscription-Based Customers In 2023 YoY
30 Jan 24
News
12 Health Care Stocks Moving In Monday's After-Market Session
29 Jan 24
Movers
Press releases
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
19 Apr 24
Press Releases
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
17 Apr 24
Press Releases
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
26 Mar 24
Press Releases
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
25 Mar 24
Press Releases
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
13 Mar 24
Press Releases
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
30 Jan 24
Press Releases